We are live on ! Find out more
CARM

Carisma Therapeutics

Delisted

CARM was delisted on the 10th of October, 2025.

29 hedge funds and large institutions have $11.5M invested in Carisma Therapeutics in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

38% more capital invested

Capital invested by funds: $8.34M → $11.5M (+$3.2M)

16% more funds holding

Funds holding: 2529 (+4)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

99% less call options, than puts

Call options by funds: $1K | Put options by funds: $93K

Holders
29
Holders Change
+4
Holders Change %
+16%
% of All Funds
0.77%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
12
Increased
10
Reduced
2
Closed
6
Calls
$1K
Puts
$93K
Net Calls
-$92K
Net Calls Change
-$92K
Name Holding Trade Value Shares
Change
Change in
Stake
AG
26
Advisor Group
Arizona
$1K
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$1K
Renaissance Technologies
28
Renaissance Technologies
New York
-$198K -5,925 Closed
TSS
29
Two Sigma Securities
New York
-$42K -1,271 Closed
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
-$25K -750 Closed
Goldman Sachs
31
Goldman Sachs
New York
-$22K -667 Closed
GC
32
Guggenheim Capital
Illinois
-$17K -517 Closed
Group One Trading
33
Group One Trading
Illinois
-$2.23K -30 Closed
Bank of America
34
Bank of America
North Carolina
+$447 +6 +300%

CARM Hedge Fund Activity: Q3 2016 in Review

29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2016, worth a combined $11.5M — up 38% from $8.34M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CARM positions and 6 closed out — a net gain of 6 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock Institutional Trust, adding an estimated $854K. The largest seller was Boxer Capital, cutting an estimated $931K.

  • 29 institutional investors held Carisma Therapeutics (CARM) as of Q3 2016, up from 25 in Q2 2016.
  • Funds reported $11.5M of Carisma Therapeutics stock for Q3 2016, up 38% quarter-over-quarter.
  • 12 funds opened new Carisma Therapeutics positions in Q3 2016 and 6 closed out, a net change of +6 holders.
  • The largest Carisma Therapeutics buyer in Q3 2016 was BlackRock Institutional Trust, an estimated $854K added.
  • The largest Carisma Therapeutics seller in Q3 2016 was Boxer Capital, an estimated $931K sold.

Based on aggregated 13F filings for Q3 2016.